Publicaciones en las que colabora con Carlos Alfaro Alegría (13)

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

2016

  1. Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)

    Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936

2015

  1. Functional expression of CD137 (4-1BB) on T helper follicular cells

    OncoImmunology, Vol. 4, Núm. 12

  2. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice

    Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478

2013

  1. Lymphatic endothelium forms integrin-engaging 3d structures during DC transit across inflamed lymphatic vessels

    Journal of Investigative Dermatology, Vol. 133, Núm. 9, pp. 2276-2285

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  2. Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy

    PLoS ONE, Vol. 7, Núm. 12

2011

  1. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy

    International Journal of Cancer, Vol. 128, Núm. 1, pp. 105-118

2010

  1. Interferon producing killer dendritic cells (IKDC): A matter of controversy

    Inmunologia, Vol. 29, Núm. 1, pp. 50-55

  2. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 8, pp. 1223-1233

2009

  1. Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?

    Immunotherapy, Vol. 1, Núm. 5, pp. 845-853

  2. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

    European Journal of Immunology, Vol. 39, Núm. 9, pp. 2424-2436

2008

  1. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

    Clinical Cancer Research, Vol. 14, Núm. 21, pp. 6895-6906